World Fusion

What World Fusion does

World Fusion Co., Ltd. (株式会社ワールドフュージョン) is a Tokyo-based bioinformatics company founded in 1996 that operates as a self-stated pioneer in fusing biotechnology and IT (FUSION). The company develops and distributes a portfolio of genome and metagenome analysis software, microbiome testing services, and AI-driven drug discovery platforms, targeting Japanese pharmaceutical, biotechnology, cosmetics, food, and academic research institutions. Its core proprietary products include Metagenome@KIN (16S rRNA/ITS metagenome analysis), WHMetagenome@KIN (shotgun metagenome), @KIN Web Stat (statistical analysis web service with LEfSe/PICRUSt2/ALDEx2), CoVGAS (COVID-19 genome analysis), FluGAS (influenza subtyping), ADPKD Target (PKD1/PKD2 pathogenic mutation detection), NEXUS CNV (copy number variation), and PLA 3.0 (bioassay). The company also operates direct microbiome testing services — S-KIN PRO (skin), COMA PRO (oral), and intestinal flora analysis — using proprietary databases including ~400 oral-specific bacterial species and skin-type classification reference data.

The platform layer is anchored by WeMol, an AI-driven molecular design platform covering proteins, antibodies, small molecules, and nucleic acids including mRNA, which integrates structure prediction (AlphaFold, RFDiffusion, Boltz-2, Chai-1, Protenix), immunogenicity prediction, humanization, virtual screening, and AI safety risk prediction. LSKB (Life Science Knowledge Bank) provides cloud-based AI target/biomarker exploration from literature and structured biological data, and SafetySuite integrates adverse event databases (FAERS, VAERS, JADER, VigiBase) for pharmacovigilance. World Fusion is also the exclusive Japan distributor for several international platforms: Qiagen CLC Genomics Workbench, WeComput WeMol, OmniTier CompStor, Chemotargets Deep Drug Discovery, BioNano Nexus CNV, SAPIO LIMS/ELN, and Scarab Genomics Clean Genome E. coli strains.

The company generates revenue through three streams: software licensing (annual and perpetual PC/network licenses for bioinformatics products), contract analysis services (per-sample microbiome testing, genome secondary/tertiary analysis, drug discovery research), and cloud subscription platforms (@KIN Web Stat, LSKB, WeMol, SafetySuite). Pricing is denominated in JPY, with academic discounts of 25% and active campaign pricing (e.g., 3,000 JPY per flora reanalysis sample, 247,500 JPY academic annual @KIN Web Stat, 10,000-35,000 JPY per genome analysis sample). GTM is direct-sales-led through the company website with inquiry forms, supplemented by monthly webinars and exhibitions at Japanese academic conferences (JSCCS, Japanese Society for Intestinal Microbiology). The company has 1-10 employees, is privately held with no parent, and has not disclosed external funding.

Name

World Fusion

Legal name

株式会社ワールドフュージョン

Website

https://w-fusion.co.jp

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

World Fusion is a Tokyo-based bioinformatics company (founded 1996) that develops and distributes genome/metagenome analysis software, AI drug discovery platforms, and microbiome testing services for Japanese pharmaceutical, biotechnology, cosmetics, food, and academic research institutions.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Software Publishers (5132), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Microbiome & Metagenomics Services (HLAGANAH), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Bioinformatics software
• Genome analysis tools
• Metagenome analysis
• Microbiome testing services
• AI drug discovery

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Software Licensing: Annual and perpetual licenses for bioinformatics software products including Metagenome@KIN, CLC Genomics Workbench, NANO TOOLs, CoVGAS, FluGAS, and Nexus CNV. Revenue generated through fixed PC licenses and network licenses.
2. Contract Analysis Services: Commissioned analysis services for microbiome testing (skin, oral, gut), genome sequencing, pathogen testing, and drug discovery research. Revenue is per-sample or per-project.
3. Cloud Software Subscriptions: Cloud-based platforms including LSKB, WeMol, @KIN Web Stat, and SafetySuite offered on annual subscription basis.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

World Fusion develops and sells bioinformatics software and provides contract analysis services for genome, metagenome, and microbiome analysis, along with AI-powered drug discovery platforms. Core products include Metagenome@KIN (microbiome analysis), WeMol (AI molecular design), OmniTier CompStor (NGS analysis), and microbiome testing services (S-KIN, COMA PRO). The company also distributes third-party platforms like CLC Genomics Workbench and SCARAB E. coli products under exclusive Japan distribution rights.

Product overview

World Fusion offers a comprehensive bioinformatics product portfolio consisting of core analysis software tools, distributed third-party solutions, microbiome analysis services, and drug discovery platforms. The core software products include Metagenome@KIN (16S/ITS metagenome analysis), WHMetagenome@KIN (whole metagenome), CoVGAS (COVID-19), FluGAS (influenza), NANO TOOLs (long-read sequencing), ADPKD Target (kidney disease), NEXUS CNV (copy number), PLA 3.0 (bioassay), OmniTier CompStor (NGS secondary/tertiary analysis), SafetySuite (drug safety), LSKB (target exploration), and SAPIO LIMS (laboratory management). The company distributes CLC Genomics Workbench by Qiagen and SCARAB E.coli products by Scarab Genomics. Service offerings include S-KIN PRO (skin microbiome), COMA PRO (oral microbiome), intestinal/microbiome analysis, sequence data analysis, data mining, Deep Drug Discovery (D3), and in silico drug discovery services. WeMol serves as the flagship AI platform integrating antibody/protein/small molecule/nucleic acid design capabilities with NVIDIA GPU acceleration. Key AI-powered features include @KIN Web Stat for automated microbiome analysis and LSKB for literature-based target/biomarker discovery.

Differentiator

Problem solved

Functional benefit

Brands

• Metagenome@KIN: Microbiome analysis software for 16S rRNA, ITS, and metagenome sequencing data analysis
• WHMetagenome@KIN
• @KIN Web Stat
• S-KIN
• COMA
• WeMol
• CoVGAS
• FluGAS
• CompStor
• SafetySuite
• LSKB
• PLA 3.0
• NEXUS CNV
• NANO TOOLs
• CLC Genomics Workbench
• ADPKD Target
• SCARAB
• Deep Drug Discovery (D3)

Products and services

• Metagenome@KIN Next-generation sequencing data analysis tool for 16S rRNA and ITS metagenome analysis. Executes BLAST or PCR classifier, performs automatic species grouping and hierarchical classification with statistical comparison features. Used by researchers in microbiome research and academic institutions.
• WHMetagenome@KIN Whole metagenome analysis tool for shotgun sequencing data from Illumina sequencers. Windows-based dedicated analysis tool for microbiome profiling.
• CLC Genomics Workbench Comprehensive NGS analysis software by Qiagen Bioinformatics distributed in Japan. Supports various sequencing data types with workflow functions for complex analyses including WGS, WES, RNA-seq, and metagenomics.
• NANO TOOLs Windows-based sequence data analysis tool for Oxford Nanopore long read data. Provides reference mapping, de novo assembly, and structural variant analysis with GUI operation.
• CoVGAS COVID-19 genome analysis software for NGS data. Performs genome assembly, mutation identification, related strain identification, and toxicity information display.
• FluGAS Influenza virus HA and NA subtype auto-determination software. Analyzes genome sequencing data from high-speed sequencers and determines subtypes with segment-by-segment genome sequence determination.
• ADPKD Target Pathogenic mutation analysis software for autosomal dominant polycystic kidney disease (ADPKD). Detects mutations in PKD1 and PKD2 genes with pathogenicity classification using Japanese population genetic data.
• NEXUS CNV Genome copy number variation analysis software supporting microarray and NGS data. Enables high-speed automated analysis of over 1000 samples with flexible annotation settings.
• PLA 3.0 Bioassay data analysis software by Stegmann Systems. Recognized by EU and FDA for various bioassay types including quantitative response assays and binary assays.
• OmniTier CompStor NGS secondary and tertiary analysis system for genome disease analysis. Outputs pathogenic variant reports with integrated hardware and analysis pipeline supporting Illumina, MGI, ONT, and PacBio sequencers.
• SafetySuite Drug safety knowledge base platform integrating data from FAERS, VAERS, JADER, and VigiBase adverse event databases. Includes modules for data management, signal detection, and safety analytics across drug lifecycle.
• LSKB (Life Science Knowledge Bank) Cloud-based drug discovery target exploration system. Supports target/biomarker discovery from diseases, compound target prediction, drug repurposing, mechanism interpretation, and toxicity reference using AI literature interpretation.
• SAPIO LIMS ELN-integrated LIMS system with sample management, reagent management, workflow construction, and NGS workflow capabilities. Supports API-based external equipment integration.
• S-KIN PRO Skin microbiome analysis service using next-generation sequencers. Provides species-level bacterial and fungal analysis with swab kit, sequencing, and comparative analysis. Industry-leading track record in skin microbiome analysis.
• COMA PRO Oral bacteria examination service using oral-specific databases (HOMD and NCBI 16S). Provides risk assessment reports for periodontal disease, dental caries, and systemic disease risks with traffic-light reporting.
• Intestinal Flora/Microbiome Analysis Intestinal flora and other microbiome analysis service for 16S rRNA, ITS, and various sample types including animals, environment, disease, and food samples.
• Sequence Data Analysis Service Contract analysis service for coronavirus genome, influenza virus typing, and whole metagenome analysis using CoVGAS, FluGAS, and WHMetagenome@KIN.
• Data Mining/Annotation Service Data mining and annotation service using gene/protein/disease/compound databases and approximately 100 million compound activity records. Provides custom database creation and original analysis tool development.
• Deep Drug Discovery (D3) Drug discovery service by Chemotargets using SurfScan fragment screening and D3 platform. Generates drug candidate compounds from protein structures considering synthetic feasibility and binding affinity.
• In Silico Drug Discovery Exploration In silico drug discovery service with four offerings: disease/compound target biomarker exploration, drug repurposing, phenotype screening with AI, and generative AI for literature-based hypothesis generation.
• WeMol AI-powered molecular design platform for antibodies, proteins, small molecules, and nucleic acids (mRNA). Integrates structure prediction, humanization, immunogenicity assessment, virtual screening, and MD/FEP simulations with NVIDIA GPU acceleration.
• SCARAB E.coli Products Clean Genome E. coli strains and C-Flow continuous fermentation platform by Scarab Genomics. Provides genetically stable expression hosts for vaccine antigens, recombinant proteins, and plasmid DNA production with over 1,000 stable E. coli expression strains.
• @KIN Web Stat Advanced statistical analysis web service for microbiome data combining statistical techniques (LEfSe, PICRUSt2, ALDEx2) with AI automation for bacterial information generation and expert chat.
• Pathogenic Mutation Analysis Service Contract pathogenic mutation analysis service using OmniTier CompStor. Classifies mutations as Pathogenic, Likely_pathogenic, or Benign with ACMG-compliant reports for hereditary and cancer diseases.

Quantifiable outcome

• Species-level microbiome analysis capability for skin, oral, and gut flora
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability16 records

Feature10 records

Partnerships

Eight partnerships are on record, tiered core, strategic and minor.

• WeComput TechnologycoreChannel Partner/ Reseller/ Distributor · 9 February 2026WeComput Technology developed WeMol, an AI-driven molecular design platform covering proteins, antibodies, small molecules, and nucleic acids. World Fusion serves as the distribution partner in Japan, replacing legacy systems with this AI-driven platform for antibody, small molecule optimization, cosmetics, and food industry applications.
• AnalytiCon DiscoverystrategicStrategic or Co-development Partner · 1 December 2025AnalytiCon Discovery is a German company developing natural product compounds. A joint research collaboration started December 2025 to develop natural-origin ingredients targeting the skin macrobiome. World Fusion maps AnalytiCon Discovery's natural products to target bacteria and provides in silico prediction services for efficient raw material development.
• Scarab GenomicscoreChannel Partner/ Reseller/ Distributor · 1 February 2025Scarab Genomics is the developer of Clean Genome® Technology, which removes unnecessary mobile genes (IS elements and prophages) from E. coli to achieve low mutation rates and high genetic/physiological stability. World Fusion holds exclusive distribution rights in Japan for Clean Genome® E. coli strains and C-Flow™ continuous fermentation technology, serving pharmaceutical, cosmetics, food, and industrial applications.
• ChemotargetscoreTechnology or IntegrationChemotargets is a Spanish biotech company providing the Deep Drug Discovery (D3) platform. Their platform uses SurfScan for fragment identification from protein structures, structure expansion considering synthetic accessibility, and binding affinity/safety prediction using Chemotargets Clarity methodology. World Fusion offers this as an in-house drug discovery service.
• OmniTiercoreChannel Partner/ Reseller/ DistributorOmniTier developed CompStor, an on-premise NGS secondary and tertiary analysis system for pathogenic variant detection. World Fusion distributes CompStor products and provides commissioned analysis services using the platform in Japan, serving clinical research and genetic disease testing markets.
• QiagencoreChannel Partner/ Reseller/ DistributorQiagen is the developer of CLC Genomics Workbench, a world-standard NGS data analysis software. World Fusion distributes CLC Genomics Workbench in Japan, providing sales, support, and demonstrations to academic and pharmaceutical research institutions.
• SAPIO SciencesminorChannel Partner/ Reseller/ DistributorSAPIO Sciences developed SAPIO LIMS/Exampler, an ELN-integrated LIMS system. World Fusion distributes this product in Japan, offering project management, sample management, workflow construction, and NGS analysis workflow capabilities.
• BioNano GenomicsminorChannel Partner/ Reseller/ DistributorBioNano Genomics developed Nexus CNV software for copy number variation analysis. World Fusion distributes Nexus CNV in Japan for genomic copy number analysis from microarray and next-generation sequencing data.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Benchling: Life sciences R&D cloud platform combining LIMS, ELN, and bioinformatics. Comparable to World Fusion's SAPIO LIMS distribution and broader workflow offerings for biopharma R&D teams.
• DNAnexus: Cloud-based bioinformatics platform for genomic and multi-omics data analysis. Comparable to World Fusion's CLC Genomics Workbench distribution and cloud offerings (@KIN Web Stat, LSKB) for pharma and academic customers.
• Schrödinger: Computational drug discovery platform combining physics-based simulation with ML for molecular design. Directly comparable to World Fusion's WeMol and Deep Drug Discovery (D3) offerings for pharma and cosmetics R&D.
• CosmosID: Microbiome sequencing and bioinformatics platform offering taxonomic identification and functional profiling. Directly comparable to World Fusion's Metagenome@KIN, S-KIN, and COMA PRO microbiome services for research and clinical customers.
• Chemotargets: Spanish biotech developing the Deep Drug Discovery (D3) platform for fragment-based drug discovery and safety prediction. Comparable to World Fusion's D3 distribution and integrated drug discovery services (LSKB, WeMol).

Emerging players

• Zymo Research: Microbiome analysis tools provider offering sample collection kits, sequencing services, and bioinformatics software (e.g., ZymoBIOMICS). Comparable to World Fusion's microbiome testing services (S-KIN, COMA) and analysis software (Metagenome@KIN).

Broad incumbents

• Bio-Techne: Life science tools and reagents provider with expanding bioinformatics and spatial biology offerings. Comparable to World Fusion's diversified life-science software and services portfolio for academic and pharma researchers.
• Eurofins Genomics: Global genomics services provider offering sequencing, bioinformatics, and contract research. Comparable to World Fusion's contract analysis services for genome sequencing, microbiome, and pathogenic variant analysis across pharma and academic customers.
• Illumina (Bioinformatics): Global sequencing leader offering BaseSpace and related bioinformatics tools. Comparable to World Fusion as a broad incumbent providing end-to-end NGS workflow solutions including secondary/tertiary analysis (overlaps with CompStor).
• Qiagen (CLC Genomics): Global leader in sample-to-insight molecular testing solutions, including CLC Genomics Workbench which World Fusion distributes in Japan. Comparable as both a partner and broader competitor in bioinformatics software and NGS analysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/world_fusion
• Facebookfacebook.com/WorldFusionCoLTD

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about World Fusion